Skip Navigation

Cardiovascular Research 2006 69(2):402-411; doi:10.1016/j.cardiores.2005.10.015
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yang, L.-Z.
Right arrow Articles by Pieske, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, L.-Z.
Right arrow Articles by Pieske, B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Urocortin II enhances contractility in rabbit ventricular myocytes via CRF2 receptor-mediated stimulation of protein kinase A

Li-Zhen Yanga,1, Jens Kockskämperb,1, Frank R. Heinzelb, Michael Hauberb, Stefanie Waltherb, Joachim Spiessa,* and Burkert Pieskeb

aDepartment of Molecular Neuroendocrinology, Max Planck Institute for Experimental Medicine, Hermann-Rein-Str. 3, D-37075 Göttingen, Germany
bDepartment of Cardiology and Pneumology, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, D-37075 Göttingen, Germany

* Corresponding author. Tel.: +49 551 3899 308; fax: +49 551 3899 359. Email address: spiess{at}em.mpg.de

Objective: Urocortin II (UcnII), a peptide of the corticotropin-releasing factor (CRF) family, exerts profound actions on the cardiovascular system. Direct effects of UcnII on adult cardiomyocytes have not been evaluated before. Our aim was to characterize functional effects of UcnII on cardiomyocytes and to elucidate the underlying signaling pathway(s) and cellular mechanisms.

Methods: Rabbit ventricular cardiomyocytes were stimulated at 0.5 Hz (22–25 °C). Unloaded cell shortening (FS, edge detection), [Ca2+]i transients (Fluo-4), and L-type Ca2+ currents (ICa, whole-cell patch clamping) were measured. Sarcoplasmic reticulum (SR) Ca2+ load was assessed by rapid application of caffeine (20 mmol/L).

Results: UcnII increased cell shortening and accelerated relaxation in a time- and concentration-dependent manner (EC50: 10.7 nmol/L). The inotropic effect of UcnII was maximal at 100 nmol/L (35% ± 11% increase in FS, n=8, P<0.05). The inotropic and lusitropic actions of UcnII were largely eliminated by inhibition of CRF2 receptors (10 nmol/L antisauvagine-30, n=5) or protein kinase A (PKA, 500 nmol/L H-89, n=5). UcnII increased [Ca2+]i transient amplitude (by 63% ± 35%, n=7, P<0.05) and decreased the time constant for decay (from 800 ± 63 to 218 ± 27 ms, n=7, P<0.001). UcnII also increased SR Ca2+ load (by 19% ± 7%, n=7, P<0.05) and fractional Ca2+ release (from 57% ± 7% to 98% ± 2%, n=7, P<0.01). ICa was augmented by 32.7% ± 10.0% (n=9, P<0.05) and the ICaV relationship was shifted by –15 mV during UcnII treatment.

Conclusion: UcnII exerts positive inotropic and lusitropic effects in cardiomyocytes via CRF2 receptor-mediated stimulation of PKA which augments ICa and SR Ca2+ load to increase SR Ca2+ release and [Ca2+]i transients.

KEYWORDS Peptide hormones; Myocytes; E–c coupling; Protein kinase A; SR (function)


1 These authors contributed equally to this work.

Time for primary review 17 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
E. Calderon-Sanchez, C. Delgado, G. Ruiz-Hurtado, A. Dominguez-Rodriguez, V. Cachofeiro, M. Rodriguez-Moyano, A. M. Gomez, A. Ordonez, and T. Smani
Urocortin induces positive inotropic effect in rat heart
Cardiovasc Res, September 1, 2009; 83(4): 717 - 725.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. E. Davis, C. J. Pemberton, T. G. Yandle, S. F. Fisher, J. G. Lainchbury, C. M. Frampton, M. T. Rademaker, and M. Richards
Urocortin 2 infusion in human heart failure
Eur. Heart J., November 1, 2007; 28(21): 2589 - 2597.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.